Related Experiment Videos
Crying-induced bronchospasm in childhood asthma: response to medical management
Insights
Crying-induced bronchospasm (CIB) in children with asthma significantly improved with environmental and pharmacologic treatments. Further reduction in CIB wheezing may benefit from nebulized medications or behavioral interventions.
Area of Science:
- Pediatric Pulmonology
- Asthma Research
- Clinical Pediatrics
Background:
- Crying-induced bronchospasm (CIB) is a common asthma symptom in children.
- CIB involves cough or wheeze lasting ≥5 minutes during or after crying.
- Effective management strategies for CIB are crucial.
Purpose of the Study:
- To evaluate the effectiveness of environmental and pharmacologic interventions for CIB.
- To assess symptom reduction in children with CIB asthma.
- To identify potential areas for improved CIB symptom management.
Main Methods:
- A 6-month clinical treatment study involving 60 CIB patients.
- Interventions included environmental modifications and pharmacologic treatments (xanthines, beta-agonist stimulants, corticosteroids).
- Symptom changes in both CIB and non-CIB groups were analyzed.
Main Results:
- Significant reduction in both CIB (P = .007) and non-CIB (P = .0005) symptoms observed.
- CIB asthma showed a lesser reduction in wheezing compared to non-CIB asthma (P < .001).
- This indicates a differential response to the applied treatments.
Conclusions:
- Environmental and pharmacologic interventions are effective in reducing CIB symptoms.
- Nebulized medications and behavioral interventions may offer additional benefits for CIB wheezing.
- Further research into targeted CIB therapies is warranted.
Abstract:
Crying-induced bronchospasm (CIB), cough and/or wheeze greater than or equal to 5 minutes during or after crying behavior, is a common feature of childhood asthma. Sixty CIB patients were evaluated during a 6-month clinical treatment study consisting of environmental and pharmacologic (xanthines, beta-agonist stimulants, and corticosteroids) interventions. Both CIB (P = .007) and non-CIB (P = .0005) symptoms were significantly reduced. CIB asthma had lesser reduction in wheezing than non-CIB (P less than .001), suggesting that nebulized medication and/or behavioral interventions may be of benefit to further reduce CIB symptoms.